These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10170205)

  • 1. Lessons from formulary decisionmaking.
    Langley PC
    Qual Lett Healthc Lead; 1997 Sep; 9(8):10-3. PubMed ID: 10170205
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomic analysis in formulary decisions: an international perspective.
    Johnson JA; Bootman JL
    Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics and the formulary decision-making process.
    Bakst A
    Hosp Formul; 1995 Jan; 30(1):42-50. PubMed ID: 10172201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of our national survey. Current formulary decision-making strategies and new factors influencing the process.
    Formulary; 1995 Aug; 30(8):462-70. PubMed ID: 10151734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic series: Part 3. Applying pharmacoeconomic and quality-of-life measures to the formulary management process.
    Skaer TL
    Hosp Formul; 1993 Jun; 28(6):577-84. PubMed ID: 10126586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
    Crane VS
    Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to develop a proactive formulary system.
    Crane VS; Gonzalez ER; Hull BL
    Hosp Formul; 1994 Oct; 29(10):700-2, 704-8, 710. PubMed ID: 10137847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and quality considerations in antibiotic formulary management.
    Ritchie DF
    Pharm Pract Manag Q; 1996 Jul; 16(2):4-8. PubMed ID: 10161610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How might cost effectiveness, quality of life, and outcomes data be used by government regulators?
    Gatty B
    Hosp Formul; 1994 Jan; 29(1):70, 69. PubMed ID: 10131268
    [No Abstract]   [Full Text] [Related]  

  • 12. Raising the bar in the formulary decision process.
    Navarro RP
    Manag Care Interface; 1999 Jul; 12(7):51, 54. PubMed ID: 10539501
    [No Abstract]   [Full Text] [Related]  

  • 13. The Orphan Drug Act: an engine of innovation? At what cost?
    Rohde DD
    Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
    [No Abstract]   [Full Text] [Related]  

  • 14. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a flexible formulary for a Veterans Administration hospital.
    Kittel JF; Swatzell RH; Williams MP; Forrester CW; Bancroft WH
    Hosp Formul; 1978 Jan; 13(1):46-8. PubMed ID: 10306086
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rethinking formulary strategy: management and measurement considerations.
    Nugent ME
    Am J Manag Care; 1999 Sep; 5(9):1202-4. PubMed ID: 10621084
    [No Abstract]   [Full Text] [Related]  

  • 19. Should providers pursue disease management?
    MacStravic S
    Health Care Strateg Manage; 1998 Apr; 16(4):1, 19-23. PubMed ID: 10178050
    [No Abstract]   [Full Text] [Related]  

  • 20. Considering cost effectiveness in the hospital setting.
    Hosp Cost Manag Account; 1997 Jan; 8(10):1-4. PubMed ID: 10163840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.